Gene transfer to suppress bone marrow alkylation sensitivity

Mutation Research - Reviews in Mutation Research

Volumn 462, Issue 2-3, 2000, Pages 107-120

  Roth, Richard B ^a   Samson, Leona D ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Alkylating agent; Bone marrow; DNA repair; Gene therapy; MGMT gene transfer; O6 methylguanine DNA methyltransferase

Indexed keywords

ALKYLATING AGENT; CARMUSTINE; CHLORAMBUCIL; CHLORMETHINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DNA METHYLTRANSFERASE; IFOSFAMIDE; LOMUSTINE; MELPHALAN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MITOMYCIN C; PROCARBAZINE; STREPTOZOCIN; TEMOZOLOMIDE; THIOTEPA; URAMUSTINE;

ALKYLATION; BONE MARROW CELL; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; DNA REPAIR; GENE THERAPY; GENE TRANSFER; HUMAN; MUTANT; PRIORITY JOURNAL; REVIEW;

EID: 0034027863     PISSN: 13835742     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1383-5742(00)00021-1     Document Type: Article

References (107)

1. A.W. Prestayko, et al. (Eds.), Nitrosoureas: Current Status and New Developments, Academic Press, London, 1981.
2. S.E. Salmon, A.C. Sartorelli, Cancer Chemotherapy, in: B.G. Katzung (Ed.), Basic and Clinical Pharmacology, 4th edn., Appleton and Lange, Norwalk, CT, 1989, pp. 683-715.
3. Bergsagel D.E., Bailey A.J., Langley G.R., MacDonald R.N., White D.F., Miller A.B. The chemotherapy on plasma-cell myeloma and the incidence of acute leukemia. N. Engl. J. Med. 301:1979;743-748.
4. Boice J.D. Jr., Greene M.H., Killen J.Y. Jr., Ellenberg S.S., Keehn R.J., McFadden E., Chen T.T., Fraumeni J.F. Jr. Leukemia and preleukemia after adjuvant treatment of gastrointestinal cancer with semustine (methyl-CCNU). N. Engl. J. Med. 309:1983;1079-1084.
5. Pedersen-Bjergaard J., Ersboll J., Sorensen J.M., Keiding N., Larsen S.O., Philip P., Larsen M.S., Schultz H., Nissen N.I. Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin's lymphomas. Comparison with results obtained in patients treated for Hodgkin's disease and ovarian carcinoma with other alkylating agents. Ann. Intern. Med. 103:1985;195-200.
6. Preussmann R. Carcinogenicity of nitrosoureas in humans. IARC Sci. Publ. 78:1986;223-229.
7. Curtis R.E., Boice J.D. Jr., Moloney W.C., Ries L.G., Flannery J.T. Leukemia following chemotherapy for breast cancer. Cancer Res. 50:1990;2741-2746.
8. Pedersen-Bjergaard J., Phiip P., Larsen S.O., Andersson M., Daugaard G., Ersboll J., Hansen S.W., Hou-Jensen K., Nielsen D., Sigsgaard T.C., Specht L., Osterlind K. Therapy-related myelodysplasia and acute myeloid leukemia. Cytogenetic characteristics of 115 consecutive cases in seven cohorts of patients treated intensively for malignant diseases in the Copenhagen study. Leukemia. 7:1993;1975-1986.
9. Erickson L.C., Laurent G., Sharkey N.A., Kohn K.W. DNA cross-linking and monoadduct repair in nitrosourea-treated human tumour cells. Nature. 288:1980;727-729.
10. Shulman L.N. The biology of alkylating-agent cellular injury. Hematol. Oncol. Clin. North Am. 7:1993;325-335.
11. Lawley P.D., Phillips D.H. DNA adducts from chemotherapeutic agents. Mutat. Res. 355:1996;13-40.
12. E.C. Friedberg, G.C. Walker, W. Siede, DNA repair and mutagenesis, American Society for Microbiology, 1995.
13. Kohn K.W. Interstrand cross-linking of DNA by 1, 3-bis(2-chloroethyl)-1-nitrosoureas and other 1-(2-haloethyl)-1-nitrosoureas. Cancer Res. 37:1977;1450-1454.
14. G.J. Goldenberg, M.J. Moore, Nitrogen mustards, in: B.A. Teicher (Ed.), Cancer Therapeutics - Experimental and Clinical Agents, Humana Press, Totowa, NJ, 1997, pp. 1-22.
15. Engelward B.P., Allan J.M., Dreslin A.J., Kelly J.D., Wu M.M., Gold B., Samson L.D. A chemical and genetic approach together define the biological consequences of 3-methyladenine lesions in the mammalian genome. J. Biol. Chem. 273:1998;5412-5418.
16. Goldmacher V.S., Cuzick R.A. Jr., Thilly W.G. Isolation and partial characterization of human cell mutants differing in sensitivity to killing and mutation by methylnitrosoureas and N-methyl-N′-nitro-N-nitrosoguanidine. J. Biol. Chem. 261:1986;12462-12471.
17. Kat A., Thilly W.G., Fang W.-H., Longley M.J., Li G.-M., Modrich P. An alkylation-tolerant, mutator human cell line is deficient in strand-specific mismatch repair. Proc. Natl. Acad. Sci. 90:1993;6424-6428.
18. Branch P., Aquilina G., Bignami M., Karran P. Defective mismatch binding and a mutator phenotype in cells tolerant to DNA damage. Nature. 362:1993;652-654.
19. 6-methylguanine in DNA inhibits DNA replication and stimulates DNA repair synthesis in vitro. Ann. N.Y. Acad. Sci. 726:1994;340-342.
20. Newlands E.S., Stevens M.F.G., Wedge S.R., Wheelhouse R.T., Brock C. Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat. Rev. 23:1997;35-61.
21. Hickman M.J., Samson L.D. Role of DNA mismatch repair and p53 in signaling of apoptosis by alkylating agents. Proc. Natl. Acad. Sci. 96:1999;10764-10769.
22. Toft N.J., Winton D.J., Kelly J., Howard L.A., Dekker M., Riele H., Arends M.J., Wyllie A.H., Margison G.P., Clarke A.R. Msh2 status modulates both apoptosis and mutation frequency in the murine small intestine. Proc. Natl. Acad. Sci. 96:1999;3911-3915.
23. Soloway M.S., Ford K.S. Thiotepa-induced myelosuppression: review of 670 bladder instillations. J. Urol. 130:1983;889-891.
24. Ahmed A.R., Hombal S.M. Cyclophosphamide (Cytoxan). A review on relevant pharmacology and clinical uses. J. Am. Acad. Dermatol. 11:1984;1115-1126.
25. Eisenbrand G., Berger M.R., Brix H.P., Fischer J.E., Muhlbauer K., Nowrousian M.R., Przybilski M., Schneider M.R., Stahl W., Tang W., Zelezny O., Zeller W.J. Nitrosoureas. Modes of action and perspectives in the use of hormone receptor affinity carrier molecules. Acta Oncol. 28:1989;203-211.
26. Feld R. Complications associated with the treatment of small cell lung cancer. Lung Cancer. 10:1994;S307-S317.
27. Khayat D., Giroux B., Berille J., Cour V., Gerard B., Sarkany M., Bertrand P., Bizzari J.P. Fotemustine in the treatment of brain primary tumors and metastases. Cancer Invest. 12:1994;414-420.
28. Frei J.V., Venitt S. Chromosome damage in the bone marrow of mice treated with the methylating agents methyl methanesulphonate and N-methyl-N-nitrosourea in the presence or absence of caffeine, and its relationship with thymoma induction. Mutat. Res. 29:1975;89-96.
29. Glassner B.J., Weeda G., Allan J.M., Broekhof J.L.M., Carls N.H.E., Donker I., Engelward B.P., Hampson R.J., Hersmus R., Hickman M.J., Roth R.B., Warren H.B., Wu M.M., Hoeijmakers J.H.J., Samson L.D. DNA repair methyltransferase (Mgmt) knockout mice are sensitive to the lethal effects of chemotherapeutic alkylating agents. Mutagenesis. 14:1999;339-347.
30. Tates A.D., Natarajan A.T., De Vogel N., Meigers M. A correlative study on the genetic damage induced by chemical mutagens in bone marrow and spermatogonia of mice: III. 1,3-bis(2-chloroethyl)-3-nitrosourea (BCNU). Mutat. Res. 44:1977;87-95.
31. Schein P.S., Bull J.M., Doukas D., Hoth D. Sensitivity of human and murine hematopoietic precursor cells to 2-[3-(2-chloroethyl)-3-nitrosoureido]-D-glucopyranose and 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Res. 38:1978;257-260.
32. Bedford P., Berger M.R., Eisenbrand G., Schmahl D. The level of DNA interstrand crosslinking in bone marrow parallels the extent of myelosuppression in mice treated with four chloroethylnitrosoureas. J. Cancer Res. Clin. Oncol. 108:1984;141-147.
33. Gordon M.Y., Goldman J.M., Gordon-Smith E.C. 4-Hydroperoxycyclophosphamide inhibits proliferation by human granulocyte-macrophage colony-forming cells (GM-CFC) but spares more primitive progenitor cells. Leuk. Res. 9:1985;1017-1021.
34. Maze R., Moritz T., Williams D.A. Increased survival and multilineage hematopoietic protection from delayed and severe myelosuppressive effects of a nitrosourea with recombinant interleukin-11. Cancer Res. 54:1994;4947-4951.
35. 6-methylguanine methyltransferase gene into repair-deficient human cells and restoration of cellular resistance to N-methyl-N′-nitro-N-nitrosoguanidine. Mutat. Res. 166:1986;135-141.
36. Samson L., Derfler B., Waldstein E.A. Suppression of human DNA alkylation-repair defects by Escherichia coli DNA-repair genes. Proc. Natl. Acad. Sci. 83:1986;5607-5610.
37. Brennand J., Margison G.P. Reduction of the toxicity and mutagenicity of alkylating agents in mammalian cells harboring the Escherichia coli alkyltransferse gene. Proc. Natl. Acad. Sci. 83:1986;6292-6296.
38. Kataoka H., Hall J., Karran P. Complementation of sensitivity to alkylating agents in Escherichia coli and Chinese hamster ovary cells by expression of a cloned bacterial DNA repair gene. EMBO J. 5:1986;3195-3200.
39. 6 alkylguanine-DNA alkyltransferase activity in human myeloid cells. J. Clin. Invest. 76:1985;2106-2114.
40. 6-alkylguanine-DNA alkyltransferase activity based on cellular DNA content in human, rat and mouse tissues. Carcinogenesis. 7:1986;745-749.
41. 6-alkylguanine during DNA synthesis in murine bone marrow hematopoietic precursors. Cancer Res. 47:1987;89-95.
42. Jelinek J., Kleibl K., Dexter T.M., Margison G.P. Transfection of murine multi-potent haemopoietic stem cells with an E. coli alkyltransferase gene confers resistance to the toxic effects of alkylating agents. Carcinogenesis. 9:1988;81-87.
43. Allay J.A., Dumenco L.L., Koc O.N., Liu L., Gerson S.L. Retroviral transduction and expression of the human alkyltransferase cDNA provides nitrosourea resistance to hematopoietic cells. Blood. 85:1995;3342-3351.
44. Moritz T., Mackay W., Glassner B.J., Williams D.A., Samson L. Retrovirus-mediated expression of a DNA repair protein in bone marrow protects hematopoietic cells from nitrosourea-induced toxicity in vitro and in vivo. Cancer Res. 55:1995;2608-2614.
45. Maze R., Carney J.P., Kelley M.R., Glassner B.J., Williams D.A., Samson L. Increasing DNA repair methyltransferase levels via bone marrow stem cell transduction rescues mice from the toxic effects of 1,3-bis(2-chloroethyl)-1-nitrosourea, a chemotherapeutic alkylating agent. Proc. Natl. Acad. Sci. U. S. A. 93:1996;206-210.
46. 6-methylguanine DNA methyltransferase complementary DNA. J. Immunol. 158:1997;1006-1013.
47. Levy J.A. The multifaceted retrovirus. Cancer Res. 46:1986;5457-5468.
48. Varmus H. Retroviruses. Science. 240:1988;1427-1435.
49. Robbins P.D., Ghivizzani S.C. Viral vectors for gene therapy. Pharmacol. Ther. 80:1998;35-47.
50. 6-alkylguanine-DNA-alkyltransferase. Blood. 87:1996;1957-1961.
51. Allay J.A., Koc O.N., Davis B.M., Gerson S.L. Retroviral-mediated gene transduction of human alkyltransferase complementary DNA confers nitrosourea resistance to human hematopoietic progenitors. Clin. Cancer Res. 2:1996;1353-1359.
52. Allay J.A., Davis B.M., Gerson S.L. Human alkyltransferase-transduced murine myeloid progenitors are enriched in vivo by BCNU treatment of transplanted mice. Exp. Hematol. 25:1997;1069-1076.
53. 6-alkylguanine-DNA-alkyltransferase protects human epithelial and hematopoietic cells against chloroethylating agent toxicity. Hum. Gene Ther. 10:1999;301-310.
54. Podsakoff G., Wong K.K. Jr., Chatterjee S. Efficient gene transfer into nondividing cells by adeno-associated virus-based vectors. J. Virol. 68:1994;5656-5666.
55. 6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents. Proc. Natl. Acad. Sci. 87:1990;5368-5372.
56. 6-benzylguanine. Biochemistry. 32:1993;11998-12006.
57. 6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res. 50:1990;6119-6129.
58. Harris L.C., Marathi U.K., Edwards C.C., Houghton P.J., Srivastava D.K., Vanin E.F., Sorrentino B.P., Brent T.P. Retroviral transfer of a bacterial alkyltransferase gene into murine bone marrow protects against chloroethylnitrosourea cytotoxicity. Clin. Cancer Res. 1:1995;1359-1368.
59. 6-benzylguanine. Cancer Res. 54:1994;6221-6227.
60. 6-benzylguanine. Cancer Res. 57:1997;2007-2012.
61. Encell L.P., Coates M.M., Loeb L.A. Engineering human DNA alkyltransferases for gene therapy using random sequence mutagenesis. Cancer Res. 58:1998;1013-1020.
62. 6-benzylguanine plus 1,3-bis(2-chloroethyl)-1-nitrosourea. Proc. Natl. Acad. Sci. U. S. A. 93:1996;14088-14093.
63. 6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Res. 57:1997;5093-5099.
64. 6-alkylating agents in vitro. Gene Ther. 5:1998;835-841.
65. 6-alkylating agent induced clastogenicity by enhanced DNA repair capacity of bone marrow cells. Mutat. Res. 416:1998;1-10.
66. 6-alkylguanine-DNA alkyltransferase. Gene Ther. 5:1998;842-847.
67. Sakumi K., Shiraishi A., Shimizu S., Tsuzuki T., Ishikawa T., Sekiguchi M. Methylnitrosourea-induced tumorigenesis in MGMT gene knockout mice. Cancer Res. 57:1997;2415-2418.
68. 6-benzylguanine and temozolomide. Clin. Cancer Res. 5:1999;163-169.
69. 6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea and allows intensive therapy of 1,3-bis(2-chloroethyl)-1-nitrosourea-resistant human colon cancer xenographs. Hum. Gene Ther. 10:1999;1021-1030.
70. Deisseroth A.B., Kavanagh J., Champlin R. Use of safety-modified retroviruses to introduce chemotherapy resistance sequences into normal hematopoietic cells for chemoprotection during the therapy of ovarian cancer: a pilot trial. Hum. Gene Ther. 5:1994;1507-1522.
71. Hesdorffer C., Antman K., Bank A., Fetell M., Mears G., Begg M. Human MDR gene transfer in patients with advanced cancer. Hum. Gene Ther. 5:1994;1151-1160.
72. O'Shaughnessy J.A., Cowan K.H., Nienhuis A.W., McDonagh K.T., Sorrentino B.P., Dunbar C.E., Chiang Y., Wilson W., Goldspiel B., Kohler D., Cottler-Fox M., Leitman S., Gottesman M., Pastan I., Denicoff A., Noone M., Gress R. Retroviral mediated transfer of the human multidrug resistance gene (MDR-1) into hematopoietic stem cells during autologous transplantation after intensive chemotherapy for metastatic breast cancer. Hum. Gene Ther. 5:1994;891-911.
73. Hanania E.G., Giles R.E., Kavanagh J., Fu S.Q., Ellerson D., Zu Z., Wang T., Su Y., Kudelka A., Rahman Z., Holmes F., Hortobagyi G., Claxton D., Bachier C., Thall P., Cheng S., Hester J., Bird J.M., Chang A., Korbling M., Seong D., Cote R., Holzmayer T., Mechetner E., Heinfeld S., Berenson R., Burtness B., Edwards C., Bast R., Andreff M., Champlin R., Deisseroth A.B.et al. Results of MDR-1 vector modification trial indicate that granulocyte/macrophage colony-forming unit cells do not contribute to posttransplant hematopoietic recovery following intensive systemic therapy. Proc. Natl. Acad. Sci. U. S. A. 93:1996;15346-15351.
74. Hesdorffer C., Ayello J., Ward M., Kaubisch A., Vahdat L., Balmaceda C., Garrett T., Fetell M., Reiss R., Bank A., Antman K. Phase I trial of retroviral-mediated transfer of the human MDR1 gene as marrow chemoprotection in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation. J. Clin. Oncol. 16:1998;165-172.
75. McLachlin J.R., Eglitis M.A., Ueda K., Kantoff P.W., Pastan I.H., Anderson W.F., Gottesman M.M. Expression of a human complementary DNA for the multidrug resistance gene in murine hematopoietic precursor cells with the use of retroviral gene transfer. J. Natl. Cancer Inst. 82:1990;1260-1263.
76. Sorrentino B.P., Brandt S.J., Bodino G., Gottesman M., Pastan I., Cline A., Nienhuis A.W. Selection of drug-resistance gene in bone marrow cells in vivo after retroviral transfer of human MDR-1. Science. 257:1992;99-103.
77. + cells. Blood. 84:1994;1408-1414.
78. O.N. Koc, B.M. Davis, J.S. Reese, S.E. Friebert, S.L. Gerson, The use of genetically modified hematopoietic stem cells for cancer therapy, in: E.C. Lattine, S.L. Gerson (Eds.), Gene Therapy of Cancer, Academic Press, Boston, 1999, pp. 373-387.
79. Van Beusechem V.W., Valerio D. Gene transfer into hematopoietic stem cells of nonhuman primates. Hum. Gene Ther. 7:1996;1649-1668.
80. Peault B., Charbord P. Gene transfer into human haematopoietic stem cells. Transfus. Sci. 18:1997;291-311.
81. Dunbar C.E., Tisdale J., Yu J.M., Soma T., Zujewski J., Bodine D., Sellers S., Cowan K., Donahue R., Emmons R. Transduction of hematopoietic stem cells in humans and in nonhuman primates. Stem Cells. 15:1997;135-140.
82. Dilber M.S. Gene transfer into hematopoietic cells: progress, problems and prospects. Turk. J. Pediatr. 40:1998;307-336.
83. Williams D.A. Retroviral-fibronectin interactions in transduction of mammalian cells. Ann. N.Y. Acad. Sci. 872:1999;113-114.
84. Maze R., Hanenberg H., Williams D.A. Establishing chemoresistance in hematopoietic progenitor cells. Mol. Med. Today. 3:1997;350-358.
85. L.G. Wilke, J.J. Mule, Transfer of drug resistance genes into hematopoietic progenitors, in: E.C. Lattine, S.L. Gerson (Eds.), Gene Therapy of Cancer, Academic Press, Boston, 1999, pp. 177-200.
86. Naldini L., Blomer U., Gallay P., Oy D., Mulligan R., Gage F.H., Verma I.M., Trono D. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science. 272:1996;263-267.
87. Kay M.A., Liu D., Hoogerbrugge P.M. Gene therapy. Proc. Natl. Acad. Sci. 94:1997;12744-12746.
88. Amado R.G., Chen I.S.Y. Lentiviral vectors - the promise of gene therapy within reach? Science. 285:1999;674-676.
89. Yang Y., Vanin E.F., Whitt M.A., Fornerod M., Zwart R., Schneiderman R.D., Grosveld G., Nienhuis A.W. Inducible, high-level production of infectious murine leukemia retroviral vector particles pseudotyped with vesicular stomatitis virus G envelope protein. Hum. Gene Ther. 6:1995;1203-1213.
90. D.S. Ory, B.A. Neugeboren, R.C. Mulligan, A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes, Proc. Natl. Acad. Sci. U. S. A., 1996, pp. 11400-11406.
91. Rebel V.I., Tanaka M., Lee J.S., Hartnett S., Pulsipher M., Nathan D.G., Mulligan R.C., Sieff C.A. One-day ex vivo culture allows effective gene transfer into human nonobese diabetic/severe combined immune-deficient repopulating cells using high-titer vesicular stomatitis virus G protein pseudotyped retrovirus. Blood. 93:1999;2217-2224.
92. Yang S., Delgado R., King S.R., Woffendin C., Barker C.S., Yang Z.Y., Xu L., Nolan G.P., Nabel G.J. Generation of retroviral vector for clinical studies using transient transfection. Hum. Gene Ther. 10:1999;123-132.
93. Gossen M., Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc. Natl. Acad. Sci. U. S. A. 89:1992;5547-5551.
94. Chen S.T., Iida A., Guo L., Friedmann T., Yee J.K. Generation of packaging cell lines for pseudotyped retroviral vectors of the G protein of vesicular stomatitis virus by using a modified tetracycline inducible system. Proc. Natl. Acad. Sci. U. S. A. 93:1996;10057-10062.
95. Iida A., Chen S.T., Friedmann T., Yee J.K. Inducible gene expression by retrovirus-mediated transfer of a modified tetracycline-regulated system. J. Virol. 70:1996;6054-6059.
96. Hofmann A., Nolan G.P., Blau H.M. Rapid retroviral delivery of tetracycline-inducible genes in a single autoregulatory cassette. Proc. Natl. Acad. Sci. U. S. A. 93:1996;5185-5190.
97. Paulus W., Baur I., Boyce F.M., Breakefield X.O., Reeves S.A. Self-contained, tetracycline-regulated retroviral vector system for gene delivery to mammalian cells. J. Virol. 70(62-67):1996;153-181.
98. Moreb J., Schweder M., Suresh A., Zucali J.R. Overexpression of the human aldehyde dehydrogenase class I results in increased resistance to 4-hydroperoxycyclophosphamide. Cancer Gene Ther. 3:1996;24-30.
99. Magni M., Shammah S., Schiro R., Mellado W., Dalla-Favera R., Gianni A.M. Induction of cyclophosphamide-resistance by aldehyde-dehydrogenase gene transfer. Blood. 87:1996;1097-1103.
100. Moreb J.S., Schweder M., Gray B., Zucali J., Zori R. In vitro selection for K562 cells with higher retrovirally mediated copy number of aldehyde dehydrogenase class-1 and higher resistance to 4-hydroperoxycyclophosphamide. Hum. Gene Ther. 9:1998;611-619.
101. Letourneau S., Greenbaum M., Cournoyer D. Retrovirus-mediated gene transfer of rat glutathione S-transferase Yc confers in vitro resistance to alkylating agents in human leukemia cells and in clonogenic mouse hematopoietic progenitor cells. Hum. Gene Ther. 7:1996;831-840.
102. Kuga T., Sakamaki S., Matsunaga T., Hirayama Y., Kuroda H., Takahashi Y., Kusakabe T., Kato I., Niitsu Y. Fibronectin fragment-facilitated retroviral transfer of the glutathione-S-transferase π gene into CD34+ cells to protect them against alkylating agents. Hum. Gene Ther. 8:1997;1901-1910.
103. Niitsu Y., Takahashi Y., Ban N., Takayama T., Saito T., Katahira T., Umetsu Y., Nakajima T., Ohi M., Kuga T., Sakamaki S., Matsunaga T., Hirayama Y., Kuroda H., Homma H., Kato J., Kogawa K. A proof of glutathione S-transferase-π-related multidrug resistance by transfer of antisense gene to cancer cells and sense gene to bone marrow stem cell. Chem. Biol. Interact. 111-112:1998;325-332.
104. L. Baltzer, R. Berkery (Eds.), Oncology Pocket Guide to Chemotherapy, Mosby, Boston, 1994.
105. D.S. Fischer, M.T. Knobf, H.J. Durivage (Eds.), The Cancer Chemotherapy Handbook, Mosby, Boston, 1997.
106. 6-alkylguanine-DNA methyltransferase. Cancer Chemother. Pharmacol. 43:1999;80-85.
107. 6-alkylguanine-DNA alkyltransferase in protecting against cyclophosphamide-induced toxicity and mutagenicity. Cancer Res. 59:1999;3059-3063.